Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA. Battaglia MR, et al. Among authors: madero marroquin r. Curr Treat Options Oncol. 2024 Oct;25(10):1335. doi: 10.1007/s11864-024-01263-8. Curr Treat Options Oncol. 2024. PMID: 39312157 No abstract available.
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA. Battaglia MR, et al. Among authors: madero marroquin r. Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30. Curr Treat Options Oncol. 2024. PMID: 38814537 Review.
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
Patel AA, Yoon JJ, Johnston H, Davidson MB, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Gross I, Dean R, Kassner J, Viswabandya A, Madero-Marroquin R, Rampal RK, Guru Murthy GS, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Cursio JF, Odenike O. Patel AA, et al. Among authors: madero marroquin r. Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880. Blood Adv. 2024. PMID: 38739724 Free PMC article.
Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J, Madero-Marroquin R, Zubizarreta N, Moshier E, Tremblay D, Coltoff A, Lancman G, Fuller R, Rana M, Mascarenhas J, Jacobs SE. Caro J, et al. Among authors: madero marroquin r. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):903-911. doi: 10.1016/j.clml.2022.08.001. Epub 2022 Aug 7. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36109322
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A, Madero-Marroquin R, Wang S, Green L, Fleharty M, Dougan T, Cheng CA, Blumenstiel B, Cibulskis C, Tsuji J, Duran M, Gocke CD, Antin JH, Nikiforow S, DeZern AE, Chen YB, Ho VT, Jones RJ, Lennon NJ, Walt DR, Ritz J, Soiffer RJ, Gondek LP, Lindsley RC. Gibson CJ, et al. Among authors: madero marroquin r. J Clin Oncol. 2022 Jan 10;40(2):189-201. doi: 10.1200/JCO.21.02286. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793200 Free PMC article.
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Menghrajani K, et al. Among authors: madero marroquin r. Blood Adv. 2022 Jan 8;6(3):828-847. doi: 10.1182/bloodadvances.2021004881. Blood Adv. 2022. PMID: 34551064 Free PMC article.
13 results